Deal of the Day — limited-time pharmacy picks!
Iressa 250mg tablet

Iressa 250mg tablet

Prescription requiredRx Required

Salt Composition: Gefitinib

Expiry Date: 01/2028

Special offer

Buy at $37.06

$37.06

Inclusive of all taxes

▼

10 tablet

About The Product

Lung Cancer

Iressa 250mg Tablet is a member of the class of medications known as "anti-cancer" and is mostly prescribed to treat lung cancer. Gefitinib, an ingredient in Iressa 250mg Tablet, is a member of the class of medications known as "kinase inhibitors."

It functions by preventing an abnormal protein from causing malignant cells to proliferate. It prevents the spread of malignant cells in this way.  A chemotherapeutic drug called Iressa 250mg is used to treat non-small cell lung cancer (NSCLC).

The generic name for this drug is gefitinib. It is an inhibitor of tyrosine kinase with antitumor properties. Iressa is used as a first-line treatment for genetically mutated lung cancer.

Uses

Treatment of Non-small cell lung cancer

Side Effects

Most side effects of the Iressa 250mg tablet do not require medical attention, as they may disappear as your body adjusts to the medicine. In case these side effects become worse, consult your doctor immediately.

  • Nausea
  • Vision complications
  • Acne
  • Extreme weakness
  • Diarrhea
  • Mouth sores
  • Dry skin
  • Loss of appetite
  • Blisters of skin
  • Vomiting
  • Shortness of breath
  • Dark coloration of urine
  • Yellowing of skin and eyes

How To Use

  • Iressa 250mg tablet is prescribed by the doctor; hence, it is advisable to follow the prescription given as it is taken orally once every day, and it can be taken with or without food.
  • In case of an overdose of Iressa, contact your doctor or any healthcare provider and seek medical attention immediately.

How It Works

​Iressa 250mg Tablet functions by stopping the working of EGFR tyrosine kinase, which binds to the ATP binding site of the enzyme. EGFR refers to epidermal growth factor receptor and is often overexpressed in cancerous cells, leading to stimulation of anti-apoptotic signals.

Additionally, it causes cell proliferation as well. Iressa has antineoplastic activity, thus it stops the growth and spreading of cancerous cells.

Safety Advice

Alcohol

It is advisable not to consume alcohol while taking this medicine.

Pregnancy

Do not take Iressa 250mg tablet without consulting the doctor, in case of pregnancy.

Breast Feeding

Without a doctor's consultation, do not take this medicine if you're breastfeeding.

Driving

It is advisable not to drive or operate heavy machinery, you may feel dizzy as one of the side effects of the medicine.

Kidney

Do not take Iressa 250mg tablet without a doctor's consultation in case of kidney problems.

Liver

Share your medical history with the doctor in case of liver disease before taking this medicine.

Missed Doses

  • ​ It is advisable to avoid missing any doses of Iressa and in case you miss a dose of Gefticip consult your doctor immediately.
  • ​

FAQs

​ Iressa 250mg tablet is an anticancer medication that is primarily used in the treatment of lung cancer.

​

Reference

Fukuoka, M., et al. (2025). IDEAL‑1 trial: randomized study of gefitinib 250 mg vs 500 mg daily in pretreated advanced non‑small‑cell lung cancer. Journal of Clinical Oncology, 12(10), 300-500.

Kawashima, J., et al. (2025). Five‑year outcomes with gefitinib induction followed by chemoradiotherapy in EGFR‑mutant stage III non‑small‑cell lung cancer: LOGIK0902/OLCSG0905 phase II study. International Journal of Clinical Oncology, 30(4), 497–503 - https://pubmed.ncbi.nlm.nih.gov/39910007/

Sai, et al. (2025). Long‑term outcomes of neoadjuvant gefitinib in resectable stage II–IIIa non‑small cell lung cancer: a phase II, prospective cohort study. Lung Cancer, 10(2), 400-700 - https://pubmed.ncbi.nlm.nih.gov/39999636/

Wu, Y.-L., et al. (2023). Randomized trial of tepotinib plus gefitinib versus chemotherapy in EGFR‑mutant non‑small‑cell lung cancer with acquired resistance due to MET amplification: INSIGHT final analysis. Clinical Cancer Research, 29(10), 1879–1886 - https://pubmed.ncbi.nlm.nih.gov/36971777/

i
Trust & safety

Medical Disclaimer

Accurate, reviewed information to support informed healthcare decisions

For informational purposes only
Not a substitute for professional medical advice
Consult your doctor for diagnosis and treatment

Magicine's primary objective is to ensure that its customers receive accurate, genuine, and trustworthy information reviewed by medical experts.

The content on this website has been produced solely for informational purposes. This is not intended to take the place of medical advice and care provided by a licensed professional, though.

This information may not include all potential side effects, warnings, and details about specific lab tests, medications, and medical conditions. Please ask your doctor any questions you may have about any drug or disease.

Our goal is not to replace or substitute for the doctor-patient relationship, but to uphold and strengthen it.

Always follow advice from your doctor, pharmacist, or other licensed healthcare professional before starting, stopping, or changing any medicine or treatment.
Read full medical disclaimer in Terms & Conditions
Magicine PharmacopyCopyright 2026